{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:30:02Z","timestamp":1789612202640,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["28858"],"award-info":[{"award-number":["28858"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21815"],"award-info":[{"award-number":["21815"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["E53D23004850006"],"award-info":[{"award-number":["E53D23004850006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02185-0","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:47:30Z","timestamp":1744289250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Valeria","family":"Bica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Venafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Massacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Graziosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gualdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Minnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Sor\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elsa","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Perfetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"5405","key":"2185_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"241","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;241(5405):290\u20133.","journal-title":"Nature"},{"key":"2185_CR2","doi-asserted-by":"publisher","unstructured":"Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood [Internet]. 2000;96(10):3343\u201356. Available from: https:\/\/doi.org\/10.1182\/blood.V96.10.3343","DOI":"10.1182\/blood.V96.10.3343"},{"issue":"10","key":"2185_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"2185_CR4","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of Imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398\u2013406.","journal-title":"Leukemia"},{"issue":"2","key":"2185_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252\u201365.","journal-title":"Am J Hematol"},{"issue":"19","key":"2185_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, Rivas JD, Las, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13(19):1\u201336.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2185_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase Inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2185_CR8","doi-asserted-by":"publisher","unstructured":"Ng JJ, Ong ST. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. Curr Hematol Malig Rep [Internet]. 2022;17(6):181\u201397. Available from: https:\/\/doi.org\/10.1007\/s11899-022-00679-z","DOI":"10.1007\/s11899-022-00679-z"},{"issue":"4","key":"2185_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.leu.2404137","volume":"20","author":"JS Khorashad","year":"2006","unstructured":"Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to Imatinib. Leukemia. 2006;20(4):658\u201363.","journal-title":"Leukemia"},{"key":"2185_CR10","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez R, Dorado S, Ru\u00edz-Heredia Y, Mart\u00edn-Mu\u00f1oz A, Rosa-Rosa JM, Ribera J et al. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Sci Rep [Internet]. 2022;12(1):1\u201311. Available from: https:\/\/doi.org\/10.1038\/s41598-022-17271-3","DOI":"10.1038\/s41598-022-17271-3"},{"issue":"February","key":"2185_CR11","first-page":"1","volume":"14","author":"J Filipek-Gorza\u0142a","year":"2024","unstructured":"Filipek-Gorza\u0142a J, Kwieci\u0144ska P, Szade A, Szade K. The dark side of stemness\u2013 the role of hematopoietic stem cells in development of blood malignancies. Front Oncol. 2024;14(February):1\u201322.","journal-title":"Front Oncol"},{"issue":"1","key":"2185_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to Imatinib despite Inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409.","journal-title":"J Clin Invest"},{"issue":"3","key":"2185_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nmeth.2834","volume":"11","author":"NA Kulak","year":"2014","unstructured":"Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M. Minimal, encapsulated proteomic-sample processing applied to copy-number Estimation in eukaryotic cells. Nat Methods. 2014;11(3):319\u201324.","journal-title":"Nat Methods"},{"issue":"9","key":"2185_CR14","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41596-018-0014-9","volume":"13","author":"SJ Humphrey","year":"2018","unstructured":"Humphrey SJ, Karayel O, James DE, Mann M. High-throughput and high-sensitivity phosphoproteomics with the easyphos platform. Nat Protoc. 2018;13(9):1897\u2013916.","journal-title":"Nat Protoc"},{"issue":"9","key":"2185_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13(9):731\u201340.","journal-title":"Nat Methods"},{"issue":"1","key":"2185_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-019-0118-z","volume":"5","author":"A Liu","year":"2019","unstructured":"Liu A, Trairatphisan P, Gjerga E, Didangelos A, Barratt J, Saez-Rodriguez J. From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL. Npj Syst Biol Appl. 2019;5(1):1\u201310.","journal-title":"Npj Syst Biol Appl"},{"key":"2185_CR17","unstructured":"Patel H, Ewels P, Peltzer A, Botvinnik O, Sturm G, Moreno D et al. nf-core\/rnaseq: nf-core\/rnaseq v3.12.0 - Osmium Octopus. Zenodo. 2023."},{"issue":"3","key":"2185_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276\u20138.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2185_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41592-018-0046-7","volume":"15","author":"R Dale","year":"2018","unstructured":"Dale R, Gr\u00fcning B, Sj\u00f6din A, Rowe J, Chapman BA, Tomkins-Tinch CH, et al. Bioconda: sustainable and comprehensive software distribution for the life sciences. Nat Methods. 2018;15(7):475\u20136.","journal-title":"Nat Methods"},{"issue":"16","key":"2185_CR20","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1093\/bioinformatics\/btx192","volume":"33","author":"F Da Veiga Leprevost","year":"2017","unstructured":"Da Veiga Leprevost F, Gr\u00fcning BA, Alves Aflitos S, R\u00f6st HL, Uszkoreit J, Barsnes H, et al. BioContainers: an open-source and community-driven framework for software standardization. Bioinformatics. 2017;33(16):2580\u20132.","journal-title":"Bioinformatics"},{"issue":"4","key":"2185_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P DI Tommaso","year":"2017","unstructured":"DI Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35(4):316\u20139.","journal-title":"Nat Biotechnol"},{"issue":"20","key":"2185_CR22","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S M\u00fcller-Dott","year":"2023","unstructured":"M\u00fcller-Dott S 1, Tsirvouli E, Vazquez M, Ramirez Flores R, Badia-i-Mompel P, FalleggeR R, et al. Expanding the coverage of Regulons from high-confidence prior knowledge for accurate Estimation of transcription factor activities. Nucleic Acids Res. 2023;51(20):10934\u201349.","journal-title":"Nucleic Acids Res"},{"key":"2185_CR23","doi-asserted-by":"publisher","unstructured":"Venafra V, Sacco F, Perfetto L. SignalingProfiler 2.0 a network-based approach to bridge multi-omics data to phenotypic hallmarks. npj Syst Biol Appl [Internet]. 2024;10(1). Available from: https:\/\/doi.org\/10.1038\/s41540-024-00417-6","DOI":"10.1038\/s41540-024-00417-6"},{"issue":"18","key":"2185_CR24","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1002\/cam4.3231","volume":"9","author":"M Lewis","year":"2020","unstructured":"Lewis M, Prouzet-Maul\u00e9on V, Lichou F, Richard E, Iggo R, Turcq B, et al. A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling. Cancer Med. 2020;9(18):6739\u201351.","journal-title":"Cancer Med"},{"key":"2185_CR25","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0107wik\u0142a A, M\u0105czy\u0144ski M, Regiec A. Fda-approved drugs for hematological malignancies\u2014the last decade review. Cancers (Basel). 2022;14(1).","DOI":"10.3390\/cancers14010087"},{"issue":"6","key":"2185_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310.","journal-title":"Blood"},{"issue":"5","key":"2185_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.18632\/oncotarget.990","volume":"4","author":"JM Gerber","year":"2013","unstructured":"Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4(5):715\u201328.","journal-title":"Oncotarget"},{"issue":"2","key":"2185_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","volume":"115","author":"SK McWeeney","year":"2010","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, et al. A gene expression signature of CD34\u2009+\u2009cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with Imatinib. Blood. 2010;115(2):315\u201325.","journal-title":"Blood"},{"key":"2185_CR29","doi-asserted-by":"crossref","unstructured":"Soverini S, De Santis S, Monaldi C, Bruno S, Mancini M. Targeting leukemic stem cells in chronic myeloid leukemia: is it worth the effort? Int J Mol Sci. 2021;22(13).","DOI":"10.3390\/ijms22137093"},{"issue":"1","key":"2185_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08479-z","volume":"21","author":"M Hallal","year":"2021","unstructured":"Hallal M, Braga-Lagache S, Jankovic J, Simillion C, Bruggmann R, Uldry AC, et al. Inference of kinase-signaling networks in human myeloid cell line models by phosphoproteomics using kinase activity enrichment analysis (KAEA). BMC Cancer. 2021;21(1):1\u201315.","journal-title":"BMC Cancer"},{"key":"2185_CR31","doi-asserted-by":"crossref","unstructured":"Xu X, Yin S, Ren Y, Hu C, Zhang A, Lin Y. Proteomics analysis reveals the correlation of programmed ROS-autophagy loop and dysregulated G1\/S checkpoint with imatinib resistance in chronic myeloid leukemia cells. Proteomics [Internet]. 2022;22(1\u20132):e2100094. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34564948\/","DOI":"10.1002\/pmic.202100094"},{"issue":"6","key":"2185_CR32","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1021\/acschembio.2c00051","volume":"17","author":"GD Martyn","year":"2022","unstructured":"Martyn GD, Veggiani G, Kusebauch U, Morrone SR, Yates BP, Singer AU, et al. Engineered SH2 domains for targeted phosphoproteomics. ACS Chem Biol. 2022;17(6):1472\u201384.","journal-title":"ACS Chem Biol"},{"issue":"7","key":"2185_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2017.36","volume":"31","author":"S Reckel","year":"2017","unstructured":"Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia. 2017;31(7):1502\u201312.","journal-title":"Leukemia"},{"key":"2185_CR34","doi-asserted-by":"publisher","unstructured":"Oliinyk D, Will A, Schneidmadel FR, B\u00f6hme M, Rinke J, Hochhaus A et al. \u00b5Phos: a scalable and sensitive platform for high-dimensional phosphoproteomics. Mol Syst Biol [Internet]. 2024;20(8):972\u201395. Available from: https:\/\/doi.org\/10.1038\/s44320-024-00050-9","DOI":"10.1038\/s44320-024-00050-9"},{"key":"2185_CR35","doi-asserted-by":"publisher","unstructured":"Moreno-Lorenzana D, Avil\u00e9s-Vazquez S, Sandoval Esquivel MA, Alvarado-Moreno A, Ortiz-Navarrete V, Torres-Mart\u00ednez H et al. CDKIs p18INK4c and p57Kip2 are involved in quiescence of CML leukemic stem cells after treatment with TKI. Cell Cycle [Internet]. 2016;15(9):1276\u201387. Available from: https:\/\/doi.org\/10.1080\/15384101.2016.1160976","DOI":"10.1080\/15384101.2016.1160976"},{"issue":"4","key":"2185_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21041177","volume":"21","author":"HD Popp","year":"2020","unstructured":"Popp HD, Kohl V, Naumann N, Flach J, Brendel S, Kleiner H, et al. DNA damage and Dna damage response in chronic myeloid leukemia. Int J Mol Sci. 2020;21(4):1\u201312.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2185_CR37","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","volume":"118","author":"GV Helgason","year":"2011","unstructured":"Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy Inhibition in CML. Blood. 2011;118(8):2035\u201343.","journal-title":"Blood"},{"issue":"1","key":"2185_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cas.13442","volume":"109","author":"T Hirao","year":"2018","unstructured":"Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S. Altered intracellular signaling by Imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. Cancer Sci. 2018;109(1):121\u201331.","journal-title":"Cancer Sci"},{"issue":"4","key":"2185_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors Imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49(4):615\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2185_CR40","doi-asserted-by":"publisher","unstructured":"Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol [Internet]. 2021;113(5):632\u201341. Available from: https:\/\/doi.org\/10.1007\/s12185-021-03126-6","DOI":"10.1007\/s12185-021-03126-6"},{"key":"2185_CR41","doi-asserted-by":"crossref","unstructured":"Douglass EF, Allaway RJ, Szalai B, Wang W, Tian T, Fern\u00e1ndez-Torras A et al. A community challenge for a Pancancer drug mechanism of action inference from perturbational profile data. Cell Rep Med. 2022;3(1).","DOI":"10.1016\/j.xcrm.2021.100492"},{"key":"2185_CR42","doi-asserted-by":"publisher","unstructured":"Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P et al. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Reports Med [Internet]. 2024;5(5):101521. Available from: https:\/\/doi.org\/10.1016\/j.xcrm.2024.101521","DOI":"10.1016\/j.xcrm.2024.101521"},{"issue":"2","key":"2185_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"key":"2185_CR44","doi-asserted-by":"publisher","unstructured":"Shin JE, Kim SH, Kong M, Kim HR, Yoon S, Kee KM et al. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia. Mol Cancer [Internet]. 2023;22(1):1\u201321. Available from: https:\/\/doi.org\/10.1186\/s12943-023-01837-4","DOI":"10.1186\/s12943-023-01837-4"},{"issue":"D1","key":"2185_CR45","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol Y, Bai J, Bandla C, Garc\u00eda-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543\u201352.","journal-title":"Nucleic Acids Res"}],"updated-by":[{"DOI":"10.1186\/s12964-025-02206-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000}}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02185-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02185-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T09:19:13Z","timestamp":1745831953000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02185-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2185"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02185-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12964-025-02206-y","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12964-025-02206-y","URL":"https:\/\/doi.org\/10.1186\/s12964-025-02206-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.N. is an advisory board member of Amplify Therapeutics. No disclosures were reported by the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}